AR032896A1 - Arilalcano-sulfonamidas, composiciones farmaceuticas, un proceso para su preparacion, y el uso de las mismas para la produccion de composiciones farmaceuticas - Google Patents
Arilalcano-sulfonamidas, composiciones farmaceuticas, un proceso para su preparacion, y el uso de las mismas para la produccion de composiciones farmaceuticasInfo
- Publication number
- AR032896A1 AR032896A1 ARP010104490A ARP010104490A AR032896A1 AR 032896 A1 AR032896 A1 AR 032896A1 AR P010104490 A ARP010104490 A AR P010104490A AR P010104490 A ARP010104490 A AR P010104490A AR 032896 A1 AR032896 A1 AR 032896A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- amino
- heteroaryl
- aryl
- oxy
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 14
- 125000003282 alkyl amino group Chemical group 0.000 abstract 11
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000004414 alkyl thio group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 239000011593 sulfur Chemical group 0.000 abstract 3
- -1 tri-substituted phenyl Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 102000002045 Endothelin Human genes 0.000 abstract 1
- 108050009340 Endothelin Proteins 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005149 cycloalkylsulfinyl group Chemical group 0.000 abstract 1
- 125000005366 cycloalkylthio group Chemical group 0.000 abstract 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000005241 heteroarylamino group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 abstract 1
- 125000005368 heteroarylthio group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 abstract 1
- 125000004468 heterocyclylthio group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0009327 | 2000-09-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032896A1 true AR032896A1 (es) | 2003-12-03 |
Family
ID=8164105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010104490A AR032896A1 (es) | 2000-09-25 | 2001-09-24 | Arilalcano-sulfonamidas, composiciones farmaceuticas, un proceso para su preparacion, y el uso de las mismas para la produccion de composiciones farmaceuticas |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7091201B2 (enExample) |
| JP (1) | JP2004509874A (enExample) |
| KR (1) | KR100835770B1 (enExample) |
| CN (1) | CN1326841C (enExample) |
| AR (1) | AR032896A1 (enExample) |
| AT (1) | ATE446289T1 (enExample) |
| AU (2) | AU2002212171B2 (enExample) |
| BR (1) | BR0114082A (enExample) |
| CA (1) | CA2423351C (enExample) |
| DE (1) | DE60140263D1 (enExample) |
| ES (1) | ES2333409T3 (enExample) |
| HU (1) | HUP0303364A3 (enExample) |
| IL (1) | IL154364A0 (enExample) |
| MX (1) | MXPA03001991A (enExample) |
| NO (1) | NO20031332L (enExample) |
| NZ (1) | NZ524172A (enExample) |
| WO (1) | WO2002024665A1 (enExample) |
| ZA (1) | ZA200302292B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| DE60318219T2 (de) | 2002-08-24 | 2009-01-15 | Astrazeneca Ab | PYRIMIDINDERIVATE ALS MODULATOREN DER AKTIVITuT VON CHEMOKINREZEPTOREN |
| SE0301654D0 (sv) * | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
| SE0301653D0 (sv) * | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
| CA2557372C (en) | 2004-03-05 | 2013-01-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 antagonists |
| BRPI0514735B8 (pt) | 2004-08-28 | 2021-05-25 | Astrazeneca Ab | derivados de pirimidino sulfonamida como moduladores do receptor de quimiocina. |
| WO2007025899A1 (en) | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| MX2008002731A (es) | 2005-09-01 | 2008-03-26 | Hoffmann La Roche | Diaminopirimidinas como moduladores de p2x3 y p3x2/3. |
| CA2620129C (en) | 2005-09-01 | 2014-12-23 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| US9181231B2 (en) * | 2011-05-03 | 2015-11-10 | Agios Pharmaceuticals, Inc | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia |
| CN103864701B (zh) * | 2014-03-10 | 2016-08-24 | 常熟市金申医化制品有限责任公司 | 4-磺胺-5-甲氧基-6-氯嘧啶的制备方法 |
| SMT202300090T1 (it) | 2018-10-23 | 2023-05-12 | Step Pharma S A S | Derivati di amminopirimidina/pirazina come inibitori di ctps1 |
| US20230086703A1 (en) * | 2019-06-04 | 2023-03-23 | Step Pharma S.A.S. | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases |
| FI3980411T3 (fi) * | 2019-06-04 | 2025-10-28 | Step Pharma S A S | N-(5-(6-etoksipyratsin-2-yyli)pyridin-2-yyli)-4-(2-(etyylisulfonamido)pyrimidin-4-yyli)tetrahydro-2h-pyran-4-karboksamidi ihmisen ctps1:n estäjänä proliferatiivisten sairauksien hoitoon |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1549494A (enExample) | 1967-10-31 | 1968-12-13 | ||
| TW394761B (en) | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
| JP2790065B2 (ja) * | 1993-12-17 | 1998-08-27 | 田辺製薬株式会社 | ベンゼンスルホンアミド誘導体及びその製法 |
| US5837708A (en) * | 1994-11-25 | 1998-11-17 | Hoffmann-La Roche Inc. | Sulphonamides |
| US5739333A (en) * | 1995-05-16 | 1998-04-14 | Tanabe Seiyaku Co., Ltd. | Sulfonamide derivative and process for preparing the same |
| JP3013752B2 (ja) * | 1995-05-16 | 2000-02-28 | 田辺製薬株式会社 | スルホンアミド誘導体 |
| JP3067131B2 (ja) * | 1995-06-16 | 2000-07-17 | 田辺製薬株式会社 | 医薬組成物 |
| ATE201202T1 (de) * | 1995-12-20 | 2001-06-15 | Yamanouchi Pharma Co Ltd | Arylethensulfonamid-derivate und diese enthaltende medikamente |
| JP3116347B2 (ja) * | 1996-11-13 | 2000-12-11 | 田辺製薬株式会社 | 医薬組成物 |
| WO1998057938A1 (en) * | 1997-06-19 | 1998-12-23 | Yamanouchi Pharmaceutical Co., Ltd. | Substituted lower alkanesulfonamide derivatives and pharmaceutical composition containing the same |
| JPH11343239A (ja) * | 1998-03-31 | 1999-12-14 | Tanabe Seiyaku Co Ltd | 排尿障害の予防・治療剤 |
-
2001
- 2001-08-28 NZ NZ524172A patent/NZ524172A/en unknown
- 2001-08-28 WO PCT/EP2001/009894 patent/WO2002024665A1/en not_active Ceased
- 2001-08-28 US US10/381,568 patent/US7091201B2/en not_active Expired - Fee Related
- 2001-08-28 HU HU0303364A patent/HUP0303364A3/hu unknown
- 2001-08-28 BR BR0114082-5A patent/BR0114082A/pt not_active Application Discontinuation
- 2001-08-28 ES ES01980288T patent/ES2333409T3/es not_active Expired - Lifetime
- 2001-08-28 MX MXPA03001991A patent/MXPA03001991A/es active IP Right Grant
- 2001-08-28 KR KR1020037003599A patent/KR100835770B1/ko not_active Expired - Fee Related
- 2001-08-28 DE DE60140263T patent/DE60140263D1/de not_active Expired - Lifetime
- 2001-08-28 AU AU2002212171A patent/AU2002212171B2/en not_active Ceased
- 2001-08-28 IL IL15436401A patent/IL154364A0/xx unknown
- 2001-08-28 CA CA2423351A patent/CA2423351C/en not_active Expired - Fee Related
- 2001-08-28 JP JP2002529075A patent/JP2004509874A/ja not_active Ceased
- 2001-08-28 CN CNB01815896XA patent/CN1326841C/zh not_active Expired - Fee Related
- 2001-08-28 AU AU1217102A patent/AU1217102A/xx active Pending
- 2001-08-28 AT AT01980288T patent/ATE446289T1/de active
- 2001-09-24 AR ARP010104490A patent/AR032896A1/es not_active Application Discontinuation
-
2003
- 2003-03-24 ZA ZA200302292A patent/ZA200302292B/en unknown
- 2003-03-24 NO NO20031332A patent/NO20031332L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2423351C (en) | 2010-12-21 |
| AU2002212171B2 (en) | 2006-12-14 |
| ATE446289T1 (de) | 2009-11-15 |
| ES2333409T3 (es) | 2010-02-22 |
| KR20030029979A (ko) | 2003-04-16 |
| IL154364A0 (en) | 2003-09-17 |
| CN1326841C (zh) | 2007-07-18 |
| ZA200302292B (en) | 2004-06-30 |
| WO2002024665A8 (en) | 2002-06-06 |
| NZ524172A (en) | 2004-09-24 |
| HUP0303364A2 (hu) | 2004-03-01 |
| DE60140263D1 (de) | 2009-12-03 |
| NO20031332D0 (no) | 2003-03-24 |
| AU1217102A (en) | 2002-04-02 |
| US7091201B2 (en) | 2006-08-15 |
| JP2004509874A (ja) | 2004-04-02 |
| BR0114082A (pt) | 2003-07-22 |
| US20040102464A1 (en) | 2004-05-27 |
| KR100835770B1 (ko) | 2008-06-09 |
| NO20031332L (no) | 2003-03-24 |
| CA2423351A1 (en) | 2002-03-28 |
| WO2002024665A1 (en) | 2002-03-28 |
| HUP0303364A3 (en) | 2004-04-28 |
| CN1633418A (zh) | 2005-06-29 |
| MXPA03001991A (es) | 2003-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032896A1 (es) | Arilalcano-sulfonamidas, composiciones farmaceuticas, un proceso para su preparacion, y el uso de las mismas para la produccion de composiciones farmaceuticas | |
| AR035610A1 (es) | Pirimidin sulfamidas, intermediarios, composiciones farmaceuticas, un procedimiento para su manufactura, el uso de dichos compuestos para la produccion de composiciones farmaceuticas | |
| NO2020010I1 (no) | fostamatinib eller et farmasøytisk akseptabelt salt av fostamatinib, eller et hydrat, solvat eller N-oksid av fostamatinib eller det farmasøytisk akseptable saltet av fostamatinib, spesielt fostamatinib dinatrium, eventuelt på form av et hydrat | |
| CY1120644T1 (el) | Μικροκαψουλες παρατεταμενης αποδεσμευσης με βαση πολυ(λακτιδιο-συν-γλυκολιδιο) που περιεχουν ενα πολυπεπτιδιο και ενα σακχαρο | |
| DK1487493T3 (da) | Konjugater af cytotoksiske midler og biologisk aktive peptider | |
| ITTO20040621A1 (it) | Immunogeno sintetico per la terapia e profilassi dell'abuso di droghe e sostanze psicoattive | |
| EP1671097A4 (en) | METHOD AND COMPOSITIONS FOR PRODUCING SEPARATED TRIMERIC RECEPTOR ANALOGS AND BIOLOGICALLY ACTIVE FUSION PROTEINS | |
| DE60332093D1 (de) | Neues phenylalaninderivat | |
| NO20052739D0 (no) | CCR5-antagonister som medikamenter | |
| UY26370A1 (es) | "imidazo-5-il-aminas bicíclicas, medicamentos que las contienen, su uso para la preparación de medicamentos y procedimiento para su preparación". | |
| CL2004000788A1 (es) | Compuestos derivados de n-[2-oxo-6-(aril o heteroaril)azepan-3-il]-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxamida, antagonistas de los receptores cgrp; composicion farmaceutica; y uso del compuesto en el tratamiento del d | |
| HRP20041152B1 (hr) | Farmaceutske formulacije | |
| UY26695A1 (es) | Activadores para amino sustituidos de la fenilamida glucoquinasa | |
| ID26984A (id) | Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda | |
| GB0408874D0 (en) | All weather precision guidance of distributed projectiles | |
| CO5590894A2 (es) | Derivados de a-(n-sulfonamido)acetamida como inhibidores del peptido b-amiloideo | |
| BR0116452A (pt) | Composto, composição farmacêutica, uso de um composto | |
| CY1106239T1 (el) | ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΔΙΑΜΟΡΦΩΣΕΙΣ ΕΛΕΓΧΟΜΕΝΗΣ ΑΠΕΛΕΥΘΕΡΩΣΗΣ ΠΟΥ ΠEPΙΕΧΟΥΝ ΑΝΑΣΤΟΛΕΑ cGMP PDE-5 | |
| BRPI0415709A (pt) | esquemas terapêuticos para antagonistas de baff | |
| AR030247A1 (es) | Arileteno-sulfonamidas, composiciones farmaceuticas , procedimiento para su produccion y el uso de las mismas para la produccion de composiciones farmaceuticas | |
| DE60233251D1 (de) | 4,4-difluor-1,2,3,4-tetrahydro-5h-1-benzazepinderivate und deren salze | |
| AR013079A1 (es) | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios | |
| ATE237321T1 (de) | 20-hete antagonisten und agonisten | |
| AR013462A1 (es) | Nuevos peptidomimeticos para el tratamiento de trastornos oseos, metodos para su produccion y drogas que contienen estos compuestos | |
| ITMI20021684A1 (it) | Composizione farmaceutica di peptide nasale |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |